Incyte Announces Plans to Initiate a Phase 3 Clinical Trial of Ruxolitinib (Jakafi®) as a Treatment for Patients with COVID-19 Associated Cytokine Storm
– Incyte also intends to launch an Expanded Access Program in the United States to allow eligible patients with COVID-19
Conference Call to be on Thursday, April 9, 2020, at 4:15 PM ET LANCASTER, Calif.–(BUSINESS WIRE)–Simulations Plus, Inc. (Nasdaq: SLP)
Management to Host Conference Call / Webcast with Bronchiectasis Expert Dr. James Chalmers AUSTIN, Texas–(BUSINESS WIRE)–Savara Inc. (Nasdaq: SVRA), an
SAN DIEGO–(BUSINESS WIRE)–Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the completion of its acquisition of the core assets of Icagen’s North
NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has approved RUXIENCE™ (rituximab), a monoclonal antibody
CHARLOTTE, N.C.–(BUSINESS WIRE)–Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, is coordinating across the industry to help solve the
Hygiena, a global leader in rapid microbial detection, monitoring, and identification technology, introduced the InSite L. mono Glo Environmental Surface Screening Test. InSite L. mono Glo Environmental Surface Screening Test. InSite L. monoGlo is an easy-to-use, self-contained, environmental sampling and screening test for Listeria species and Listeria monocytogenes (L. mono).
The Pharma & Biopharma Outsourcing Association (PBOA), a trade group that represents Contract Manufacturing Organizations (CMOs) and other service providers in the bio/pharmaceutical sector, reports that many of its member companies are actively involved in helping their clients develop and produce treatments, vaccines, and diagnostics for COVID-19. PBOA’s members provide a wide array of services throughout the bio/pharma sector.
CRANBURY, N.J.–(BUSINESS WIRE)–#drugcostmanagement–MJH Life Sciences™ has announced it has acquired the Pharmacy Benefit Management Institute (PBMI) from Pharmaceutical Strategies Group
Accelerated Enrollment Solutions and Science 37 Collaborate to Provide Virtual Trial Access to Patients Globally
Also offers immediate telehealth options for clinical trials in response to need for social distancing and business continuity during COVID-19
Eisai, Biogen kick-off phase 3 testing early Alzheimer’s disease antibody, amid dropping aducanunab trial. Eisai’s US company presents AD pipeline
Eisai Co said Friday thata global Phase III clinical study (Clarity AD/Study 301) of BAN2401, an anti-amyloid beta protofibril antibody, in patients with early Alzheimer’s disease has been initiated.
ProMIS Neurosciencesissued a pres release Friday, raising urgency to selectively target the toxic oligomer with exacting precision as part of the global effort to develop disease-modifying therapies for Alzheimer’s disease (AD), upon Biogen’s and Eisai’s dropping two alte-stage clinical trials of aducanumab.
@alvogenpr subsidiary in Taiwan, Lotus Pharmaceuticals today announced capital and business collaboration agreements with Fuji Pharma in Japan, as Fuji has acquired a 2.0% stake in Lotus for approximately US$20 million (or NT$ 617 million, JPY 2.2 billion). Lotus has also acquired 3.9% stake in Fuji for an equal sum.
BOSTON–(BUSINESS WIRE)–Gelesis, a biotechnology company developing first-in-class mechanotherapeutics to treat obesity and other chronic diseases related to the gastrointestinal (GI)
SAN DIEGO–(BUSINESS WIRE)–CB Therapeutics is an innovative biotechnology company focusing on research and production of cannabinoids. The company utilizes its
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather
First Cancer Patient Receives Dose of Super-Enhancer Inhibitor GZ17-6.02, an Advanced Cancer Drug from Genzada Pharmaceuticals, at HonorHealth Research Institute
STERLING, Kan.–(BUSINESS WIRE)–Genzada Pharmaceuticals USA Inc. (Genzada), a subsidiary of Ionics Life Sciences Limited, announced today that the first patient
2018 Full-year results and business update Clinical trials set to announce key data in 2019 Invir.IO™ platform designed to deliver
SHANGHAI–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/Shanghai?src=hash" target="_blank"gt;#Shanghailt;/agt;–To accelerate the development of cell and gene therapy, ATLATL Center and Miltenyi Biotec have cooperated to build ATLATL-MACS Center
ANN ARBOR, Mich. & LANSING, Mich.–(BUSINESS WIRE)–Michigan’s premier biosciences industry trade organization, MichBio, presents its annual Michigan Biosciences Day at